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ABSTRACT: Background: Varying degrees of cortical
amyloid deposition are reported in the setting of Parkin-
sonism with cognitive impairment. We performed a sys-
tematic review to estimate the prevalence of Alzheimer
disease (AD) range cortical amyloid deposition among
patients with Parkinson’s disease with dementia (PDD),
Parkinson’s disease with mild cognitive impairment (PD-
MCI) and dementia with Lewy bodies (DLB). We
included amyloid positron emission tomography (PET)
imaging studies using Pittsburgh Compound B (PiB).
Methods: We searched the databases Ovid MEDLINE,
PubMed, Embase, Scopus, and Web of Science for
articles pertaining to amyloid imaging in Parkinsonism
and impaired cognition. We identified 11 articles using
PiB imaging to quantify cortical amyloid. We used the
metan module in Stata, version 11.0, to calculate point
prevalence estimates of patients with “PiB-positive”
studies, that is, patients showing AD range cortical Ab-
amyloid deposition. Heterogeneity was assessed. A
scatterplot was used to assess publication bias.
Results: Overall pooled prevalence of “PiB-positive”
studies across all three entities along the spectrum of
Parkinson’s disease and impaired cognition (specifically
PDD, PD-MCI, and DLB) was 0.41 (95% confidence
interval [CI], 0.24-0.57). Prevalence of “PiB-positive”
studies was 0.68 (95% CI, 0.55-0.82) in the DLB group,
0.34 (95% CI, 0.13-0.56) in the PDD group, and 0.05
(95% CI, 20.07-0.17) in the PD-MCI group.
Conclusions: Substantial variability occurs in the preva-
lence of “PiB-positive” studies in subjects with Parkin-
sonism and cognitive impairment. Higher prevalence of
PiB-positive studies was encountered among subjects
with DLB as opposed to subjects with PDD. The PD-
MCI subjects showed overall lower prevalence of PiB-
positive studies than reported findings in non–PD-
related MCI. VC 2015 International Parkinson and Move-
ment Disorder Society
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Parkinson’s disease (PD) is the second most common
neurodegenerative disorder and is characterized by pro-
gressive motor and cognitive impairments. The risk of
developing dementia in the setting of PD is two to six
times higher than in the general population, correspond-
ing to lifetime risk estimates of 30% to 80%.1,2
Parkinson’s disease with dementia (PDD) is related
closely to dementia with Lewy bodies (DLB), which is the
second most common neurodegenerative dementia,
accounting for up to 20% of dementia cases.3,4 The key
similarity between PDD and DLB is the requirement for
synucleinopathy in characteristic regional depositions in
the context of dementia. Distinction between the two
entities is based on the “1-year rule,” with subjects pre-
senting with dementia before or within 1 year of develop-
ing parkinsonism classified as DLB and those developing
dementia more than 1 y after PD diagnosis classified as
PDD.5 Although the PDD-DLB clinical classification was
hoped to improve diagnostic homogeneity and highlight
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distinctions between the two syndromes, subsequent stud-
ies have shown substantial overlap of PDD and DLB phe-
notypes in a number of clinical and neuropathological
investigations.6-9
Recently developed molecular imaging approaches
permit the detection of pathological accumulations of
Ab-amyloid plaques.10 Amyloid plaques are demon-
strated commonly in both PDD and DLB on neuro-
pathological examinations.6,8,11,12 A number of
amyloid positron emission tomography (PET) imag-
ing studies have been performed in the setting of PD,
PDD, and DLB.13-23 Although a wide range of amy-
loid deposition and relatively few subjects are present
in most individual studies, the overall impression is
that higher levels of neocortical amyloid deposition
(similar to those encountered in the setting of Alzhei-
mer’s disease [AD]) are more frequent in DLB than
PDD. Potentially more interesting is the impression
that higher levels of amyloid deposition are less fre-
quent in PD with mild cognitive impairment (MCI)
compared with frequencies reported in cognitively
normal elderly subjects.16,19,21,23 Delineating the fre-
quency of AD-range amyloid deposition in patients
with parkinsonism and cognitive impairment, specifi-
cally in the context of individual clinical subtypes (ie,
PDD, DLB, and PD with mild cognitive impairment
[PD-MCI]), is a prerequisite for understanding the
role of amyloid in the multisystem neurodegeneration
of PD. Prior amyloid imaging studies of PD and DLB
are largely smaller series with relatively heterogene-
ous subject populations and varying imaging
methods.
To help delineate important questions for future
research, we undertook a systematic review meta-
analysis of prior amyloid imaging studies of DLB, PPD,
and PD-MCI. Because of the relatively small number of
aggregate subjects and varying methods of imaging data
analysis (discussed later), we selected high (AD-range)
levels of neocortical amyloid deposition as the most
robust endpoint for comparing amyloid deposition in
the DLB, PDD, and PD-MCI groups.
The specific objective purpose of this systematic
review is to estimate the frequency of “amyloid-
positive” subjects among patients with DLB, PDD,
and PD with MCI. We define “amyloid positive” as
exhibiting AD-range cortical amyloid deposition on
brain PET imaging performed with Pittsburgh com-
pound B (PiB; hence the term “PiB-positive” also is
used) with thresholds determined by the individual
laboratories where each study was performed.
METHODS
Information Sources/Study Search Strategy
In February 2013, we systematically searched Ovid
MEDLINE, PubMed, Embase, Scopus, and Web of
Science for articles pertaining to amyloid imaging in
Parkinson’s disease dementia. The MeSH and
EMTREE vocabularies were used whenever possible,
along with keyword variations of the imaging and dis-
ease terms. The initial search was run in Ovid Medline
and then translated to the other databases (see Supple-
mental Data for the complete Ovid MEDLINE strat-
egy). In all searches, non-English studies were
excluded from the results, but no other limits or
restrictions were applied. The combined yield of all
searches was 938 citations, of which 509 were identi-
fied as duplicates in Endnote X5 (Thomson Reuters).
The resulting set of 429 unique citations were
exported into Excel and distributed to the lead author
for screening.
Study Selection
We included a study if it satisfied the following cri-
teria: human studies using PiB for amyloid brain PET
imaging in subjects with PDD or PD-MCI or DLB,
more than three subjects/disease category, and subject
mean ages included in the provided data. Studies
involving duplicated data were identified, and the
larger dataset only was included.
Data Collection and Extraction
Two reviewers (M.P., B.R.F.) independently eval-
uated each abstract for inclusion. Next, we obtained
full publications for further assessment and data
extraction. The same reviewers independently
reviewed each article and reached a final consensus for
inclusion. These reviewers abstracted the information
from the eligible articles: author, journal, year of pub-
lication, number of subjects, demographic and clinical
characteristics of subjects, as well as the method of
PiB PET image classification into positive versus nega-
tive (based on volume of distribution or based on
standard uptake values measurements). Numbers of
“PiB-positive” versus “PiB-negative” subjects per clini-
cal classification group were the main outcome of
interest extracted from the included studies.
Assessment of Methodologic Quality
Two reviewers (M.P., B.R.F.) independently assessed
the quality of each study according to the Quality
Assessment for Studies of Diagnostic Accuracy (QUA-
DAS) criteria.24 These criteria assessed adequacy of
index test description, adequacy of reference standard
likely to correctly classify disease, adequacy of refer-
ence standard test description, blinded interpretations
of index tests, absence of differential verification bias,
absence of incorporation bias, absence of partial verifi-
cation bias, whether a representative spectrum of dis-
eased patients will receive the test in practice, whether
selection criteria were clearly described, whether there
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a short period occurred between index and reference
and whether uninterpretable results were reported.
Each of these criteria were scored as “yes,” “no,” or
“unclear.” All studies classified subjects as having
DLB based on the revised consensus criteria.5 In five
of six studies that included PDD subjects, diagnosis of
PDD was based on the relative timing of dementia
and parkinsonism. Diagnosis of PD in these subjects
was based on the UK Parkinson Disease Society
(UKPDS) brain bank criteria25 in four of the studies
and on criteria proposed by Larsen et al.26 in one
study.17 Diagnosis of dementia was based on Diagnos-
tic and Statistical Manual of Mental Disorders, 4th
Edition, criteria27 in these five studies. In one of six
studies including PDD subjects, neuropsychological
testing outcomes were used to determine the presence
of dementia23 in the presence of PD. Determination of
PD-MCI was more variable and based on neuropsy-
chological testing outcomes. Representative disease
spectrum was also determined on the basis of included
range of neuropsychological testing outcomes. Any
disagreements in abstracted results between the
reviewers were resolved by discussion and consensus.
Statistical Analysis
We used the metan module in Stata, version 11.0,
to calculate the frequency estimates of PiB-positive
studies among the PDD, PD-MCI, and DLB groups,
using random effects modeling. The 95% confidence
intervals for these also were calculated. Data were
intrinsically weighed by using individual study
variances.
Assessment of Heterogeneity
Heterogeneity was assessed using the quantity I2 as
defined by I25 100% x (Q–df)/Q, where I2 is a mea-
sure of consistency across studies, Q is the Cochran’s
heterogeneity statistic, and df is the degrees of freedom.
Higgins et al.28 propose describing I2 values of 25%,
50%, and 75% as low, moderate, and high, respec-
tively, between trial heterogeneity.28 We obtained the
I2 values as an output of the metan program.
Testing for Publication Bias
A scatterplot of the estimated point prevalence ver-
sus the corresponding study’s standard error measure-
ment was used to assess publication/small sample bias.
The scatterplot should have a symmetric distribution
when publication bias is not present. A linear regres-
sion of the point prevalence of PiB-positive subjects
versus standard error measurement also was used for
publication bias assessment, with P<0.05 indicating
significant asymmetry.
Results
Study Selection
Numbers of studies screened, assessed for eligibility,
and included in the review, with reasons for exclusion
at each stage, are given in Figure 1. The search yielded
429 literature citations for potential inclusion. We
excluded a total of 389 studies because they were
review-based articles, did not include imaging, did not
specifically include PiB imaging, did not include sub-
jects with DLB or PDD, did not include human sub-
jects, or were case reports. Of the 40 studies that
fulfilled criteria, only 18 were full-length publications;
the rest of the studies were reported in abstracts
included in conference proceedings. One of the 18
studies did not include PiB data on DLB patients, one
of the studies only included one DLB subject, one
study only included three PDD subjects, and one study
included three DLB subjects. Three additional studies
were excluded based on overlapping data with the
included studies. A total of 11 studies were included
in the analysis.
Study Characteristics
The 11 included studies involved 74 subjects diag-
nosed with PDD, 99 subjects with DLB, and 60 sub-
jects with PD and mild cognitive impairment. The
studies were published between 2007 and 2013 (Table
1). Three studies were performed in Europe, six in
North America, one in Asia, and one in Australia. Six
studies determined “PiB-positive” versus “PiB-
negative” status based on measures of volume of dis-
tribution. Five studies determined “PiB-positive/neg-
ative” status based on standard uptake value
measurements of the radiotracer uptake.
Point Prevalence Estimates
Figure 2 shows the forest plot of the point preva-
lence values. The overall pooled prevalence of PiB-
positive studies in the setting of PD and cognitive
impairment is 0.41 (95% CI, 0.24-0.57). The pooled
FIG. 1. Flowchart illustrates the selection of studies. PiB, Pittsburgh
compound B; PET, positron emission tomography; PDD, Parkinson’s
disease with dementia; DLB, dementia with Lewy bodies; PD-MCI,
Parkinson’s disease with mild cognitive impairment.
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prevalence of PiB-positive scans among the DLB group
is 0.68 (95% CI, 0.55-0.82). The pooled prevalence of
PiB-positive scans among the PDD group is 0.34
(95% CI, 0.13-0.56). The pooled prevalence of PiB-
positive scans among the PD-MCI group is 0.05 (95%
CI, 20.07-0.17).
Assessment of Methodological Quality
Study quality scores ranged from 7 to 10 out of a
possible score of 11 (Fig. 3). Overall, study quality
scores were high. Almost 40% of the studies do not
include a representative disease spectrum in terms of
disease severity, with most demented subjects only
having mild disease. This likely reflects the difficulties
in performing imaging studies in patients with moder-
ate and severe dementia. Most studies did not explic-
itly state whether the interpretation of the index test
was blinded or whether a short time elapsed between
the reference and the index testing.
Assessment of Heterogeneity
The point prevalence estimates for the 11 studies
demonstrated a high level of heterogeneity using the
mixed-model analysis (I25 90%; P<0.001). The sub-
analyses of the point prevalence for the DLB and PDD
subgroups demonstrated a much higher level of heter-
ogeneity (I25 72%; P< 0.001 and I25 73%;
P< 0.001, respectively) compared with the PD-MCI
subgroup (I250%; P5 0.95).These findings highlight
the heterogeneity in these clinical syndromes, espe-
cially as the diseases evolve beyond the initial MCI
stage.
Publication Bias
As seen in the scatterplot (Fig. 4), an asymmetric
distribution of the data was seen, with a tendency of
the studies with a lower standard of error to have
higher point prevalence. Regression analysis demon-
strated a significant publication bias (bias coef-
ficient5 –4.82; P< 0.001). Again, the findings indicate
the significant heterogeneity of the investigated dis-
eases and associated effects of small samples on esti-
mates of the frequency of AD-range amyloidopathy.
Discussion
Relative timing and severity of cognitive impairment
in the setting of Parkinsonism is used to assign the
diagnoses of PD-MCI, PDD, and DLB. Despite the
acknowledged central role of amyloid plaques in AD
and a general impression that amyloid deposition is an
important contributor to cognitive impairments in syn-
ucleinopathies, relatively few in vivo imaging studies
have been performed of Ab-amyloid deposition in
dementias associated with synucleinopathy. Therefore,
our systematic review of the existing, smaller studies
in this setting is pertinent. Our results indicate sub-
stantial variability in AD-range cortical amyloid depo-
sition, as determined by PiB PET imaging positivity
among patients with Parkinsonism and cognitive
impairment classified clinically as PDD, PD-MCI, and
DLB. To frame the potential significance of this analy-
sis, a brief summary of the relationship of Ab-amyloid
deposition in the more common setting of AD follows.
Moderate to high levels of Ab-amyloid plaque den-
sity are required for pathological diagnosis of AD.29
Recent in vivo imaging studies of fibrillary amyloid
deposition with PiB and related tracers confirm that
high percentages of clinically diagnosed probable AD
patients are amyloid positive.30 The minor fractions
that are amyloid negative are probably attributable to
clinical misclassification of frontotemporal dementias
or of pure DLB as probable AD,13 with the intriguing
and recently described phenomenon of suspected non-
amyloid pathology an additional potential contribu-
tor.31 Comparative amyloid imaging and pathological
confirmatory studies support for the most part the
image-based classification of individual subject amy-
loid status.32,33 The necessary role of high-level corti-
cal amyloid deposition in AD (cascade hypothesis) is
supported by the frequency of PiB-positive findings in
MCI without PD and the significant although lower
frequency of PiB positivity in asymptomatic normal
elderly subjects.34-37 Recent study of monogenic AD
indicates onset of amyloid deposition more than a dec-
ade before symptomatic cognitive deficits, supporting
the concept that initial amyloid deposition predates
significant neurodegeneration and symptom onset.38
Similarly, recent imaging data suggest that cortical
TABLE 1. Individual study characteristics
Study Number Author Year Origin Age of Subjects
1 Burke 2011 USA DLB: 72 (54-90)
2 Edison 2008 UK DLB: 72 (62-80)
PDD: 69 (56-80)
PD-MCI: 68 (58-73)
3 Foster 2010 USA DLB: 71
PDD: 75
PD-MCI: 73
4 Gomperts 2012 USA DLB: 72
PDD: 73
PD-MCI: 69
5 Gomperts 2013 USA PD-MCI: 67
6 Jokinnen 2010 Finland PDD: 72 (56-79)
7 Kantarci 2012 USA DLB: 73 (60-87)
8 Maetzler 2009 Germany DLB: 69 (62-75)
PDD: 70 (62-80)
9 Petrou 2012 USA PDD: 70 (60-84)
PD-MCI: 70 (60-84)
10 Rowe 2007 Australia DLB: 72 (63-81)
11 Shimada 2013 Japan DLB: 73
Abbreviations: PDD, Parkinson’s disease with dementia; DLB, dementia
with Lewy bodies; PD-MCI, Parkinson’s disease with mild cognitive
impairment.
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amyloid deposition plateaus at high levels before onset
of cognitive impairment in AD.39 Against this back-
ground, our findings in synucleinopathy subjects are
significantly divergent.
Not surprisingly, and consistent with pathological
studies, a significant fraction of DLB and PDD sub-
jects had subthreshold amyloid levels, indicating that
the neurodegeneration secondary to synucleinopathy is
driving cognitive decline in these individuals. Second,
substantial differences are seen in PiB-positive preva-
lence among PDD and DLB subjects, with minimal
overlap in the 95% confidence intervals. An overall
lower frequency of PiB positivity was found in PDD
than in DLB subjects. A plausible explanation for this
observation is a cumulative effect of two major path-
ologies; the majority of previously asymptomatic sub-
jects with high neocortical amyloid burden and
significant synucleinopathy will present with dementia
and therefore be classified as having DLB (or AD if
parkinsonism is not yet clinically evident). This
“classification” bias inherent to the 1-y rule of relative
timing of dementia and parkinsonism could explain
the differential rates of PiB-positive studies among dif-
ferent diagnostic groups. Frequency of amyloidopathy
in PDD/DLB may be related to patient age as well as
disease duration. For example, the Sydney Multicenter
Study of PD showed that longer duration of disease is
increasingly accompanied by comorbid AD pathology,
especially after 5 y.40
We find a low frequency of PiB positivity in PD-
MCI compared not only with DLB and PDD but also
as compared with reports in non–PD-associated MCI.
Furthermore, the mean prevalence of amyloid positiv-
ity in PD-MCI is lower than mean values reported in
cognitively normal elderly controls, although overlap
in confidence intervals is seen with those reported in
series of normal elderly with no diagnosis of neuro-
logic disease. High neocortical amyloid deposition in
MCI and normal elderly controls is inferred to be part
of a sequential cascade leading to AD with the
FIG. 2. Forest plot of point prevalence of PiB-positive studies among the three entities encompassed by parkinsonism and cognitive impairment,
specifically PDD, DLB, and PD-MCI. The center point represents the estimated point prevalence for the respective study and the horizontal line, the
95% confidence interval for the respective study. The vertical broken line represents the pooled point prevalence, and the boundaries of the hollow
diamond represents the 95% CI of the pooled results. PDD, Parkinson’s disease with dementia; DLB, dementia with Lewy bodies; PD-MCI, Parkin-
son’s disease with mild cognitive impairment; n1, number of subjects positive for amyloid; npat, total number of patients in each study. [Color figure
can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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presence of high amyloid deposition on PET imaging
associated with high increase of risk for ultimate pro-
gression to AD. One possible explanation of this
marked discrepancy is a strong form of the selection
phenomenon suggested previously to account for the
differential frequency of high neocortical amyloid dep-
osition in PDD versus DLB. Another intriguing possi-
bility is that the PD brain is less hospitable to the
generation of fibrillar amyloid. Recent data suggest
that changes in neurotransmitter systems influence
amyloid precursor protein metabolism
significantly.41,42
Our study has limitations. None of the reviewed
reports used the true gold standard for PDD/DLB,
autopsy. Variability was seen in the degree of cogni-
tive impairment of subjects between reports, and PD-
MCI, in particular, is a heterogeneous clinical syn-
drome with variable definitions. Patients with severe
dementia were not included in most of the studies,
presumably because of inability to cooperate with the
imaging protocol. Furthermore, the age distribution,
with mean ages of approximately 70 years, is not fully
representative of the PD population as a whole. Given
expected age-associated increases in amyloid deposi-
tion, interrogating amyloidopathy at younger ages
within the disease spectrum may limit confounding
age effects and provide more insight into the role of
amyloid deposition in synucleinopathy-associated cog-
nitive impairments. Classification of dementia may be
based on varying degrees of prospective/retrospective
data in different centers. Apolipoprotein E status,
which is known to affect amyloid deposition, was not
reported in most of these studies and therefore was
not part of the analysis.43 All studies reviewed came
from tertiary referral centers, and subject recruitment
is subject to referral biases. Definite heterogeneity is
found in the PiB imaging and image processing proto-
cols across different laboratories, reflecting technical
imaging preferences and practices. Our analysis is
based on the presence of AD-range cortical Ab-
amyloid deposition, because this was the criterion
used to classify subjects as “PiB positive” and reported
in the collection of studies summarized in this system-
atic review. Our pragmatic approach of accepting
FIG. 3. Study Quality Scores. Graph illustrates study quality based on QUADAS criteria, expressed as a percentage of studies meeting each crite-
rion. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
FIG. 4. Assessing Publication Bias. The funnel plot horizontal axis
expresses treatment effect, in this instance, measured by point preva-
lence. The vertical axis expresses study size, as measured by standard
error (SE). Studies with larger standard errors have a wider confidence
interval (CI) caused by smaller sample size. The graphed vertical line rep-
resents the point prevalence, and the dashed lines represent the 95%
confidence limits for the expected distribution for published studies. The
points represent the observed distribution of the published studies. Visual
inspection of the plot demonstrates the presence of publication bias, with
many studies outside the 95% confidence limits. [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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each laboratory’s classification of PiB imaging studies
into “positive” or “negative” based on laboratory-
specific determination of this categorical outcome
attempts to moderate these technical differences
between facilities, but it is associated with inherent
limitations. One of the limitations of bridging differen-
ces between laboratories via a categorical approach to
cortical amyloid quantification analysis is the inability
to assess the significance of cortical amyloid levels
below the AD range. Such an endeavor would involve
treating cortical amyloid as a continuous variable,
which is not possible given the differences between
imaging and postprocessing parameters and associated
reported outcomes. Although PiB PET has a finite
detection threshold and cases with amyloid plaques at
biopsy or autopsy occupying less than 2% of the
microscopic field are classed as PiB negative, this is
unlikely to confound our analysis based on AD-range
cortical amyloid deposition.
Levels of Ab-amyloid deposition below AD-range
thresholds may have clinical salience in Lewy body
diseases, in which a multisystem neurodegenerative
process takes place. Our own data suggest a significant
correlation between lower than AD-range levels of
neocortical Ab-amyloid deposition and cognitive func-
tion in PD patients at risk for dementia.23 Further sup-
porting this notion of an “amplified” effect on
cognition of low levels of cortical amyloid in the set-
ting of a synucleinopathy are the neuropathologic
findings by Compta et al11 suggesting that the combi-
nation of cortical amyloid deposits and presence of
cortical Lewy bodies may be the best predictor of cog-
nitive decline in Parkinson’s disease patients. Our
group also has shown that neocortical Ab-amyloid
deposition and cholinergic degeneration are independ-
ent predictors of impaired cognition in the setting of
Parkinson’s disease. This further supports the idea of a
lower symptomatic threshold for effects of amyloidop-
athy than the levels defined in the AD population—a
concept consistent with the selection effects raised
here.
The studies reviewed contained relatively small
numbers of subjects, constraining the analytic power
of our review and explaining the significant publica-
tion/small sample size bias. We aggregated he results
of the relatively small numbers of subjects from indi-
vidual amyloid imaging studies to provide a more
robust quantitative estimate of the prevalence of amy-
loid deposition in these subject groups. Our analysis
suggests substantial variability in AD-range cortical
Ab-amyloid deposition across the entire spectrum of
patients with synucleinopathy and impaired cognition.
Establishing the prevalence and understanding the role
of amyloidopathy in parkinsonian patients with cogni-
tive impairment is important because emerging tar-
geted amyloid-related interventions may be applicable
to these patient populations. This analysis exposes the
need for prospective, systematic, larger studies
employing uniform recruitment, clinical, and imaging
characterization protocols and concurrent evaluation
of vulnerable neuronal populations in synucleinopa-
thies to clarify the roles of amyloidopathy in
synucleinopathy-related cognitive impairments. Analy-
sis of early PD and PD-MCI populations may be par-
ticularly interesting because confirmation of lower
cortical amyloid deposition in these populations may
be provide clues into the modulation of amyloid pre-
cursor protein metabolism and deposition in vivo.
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